American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 3(66), 2022
DOI: 10.1128/aac.02071-21
Full text: Download
Increasing antimicrobial resistance and medical device-related infections have led to a renewed interest in phage therapy as an alternative or adjunct to conventional antimicrobials. Expanded access and compassionate use cases have risen exponentially but have varied widely in approach, methodology, clinical situations in which phage therapy might be considered, dosing, route of administration, and outcomes.